Venture Valuation

Team

Patrik Frei

Patrik Frei

CEO Ph.D., lic. oec. HSG

Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland. He started the company over 10 years ago when he noticed a need for independent valuation services in high growth industries during a collaboration with Novartis Venture Fund, which became his first client. Since then he has been involved in over 250 valuations for investors as well as biotech, Pharma and medtech companies. Patrik graduated from the Business University of St. Gallen and completed his Ph.D thesis (”Assessment and valuation of high growth companies”) at the Swiss Federal Institute of Technology, EPFL Lausanne. Patrik was a board member and one of the original founders of Ineo, a holding company of the Swiss dental implant VC-backed firm Thommen Medical. He is also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company, where he successfully out-licensed a portfolio of 4 products. Furthermore, Patrik is member of the board of Kleinkraftwerk Birseck AG (KKBN:Berne) a publicly quoted cleantech company. Patrik’s articles have been published in a number of scientific journals including “Nature Biotechnology”, “Chimia” and other business publications (“Starting a Business in the Life Sciences: From Idea to Market” and “Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies”). He has also lectured at Seoul National University, South Korea, EPFL Lausanne, University of St. Gallen and gives regular workshops on valuation.

LinkedIn

Jost Renggli

Jost Renggli

COO & Partner lic. rer. pol. (M.A.), MAS Business IT

Jost joined Venture Valuation in 2001 and is COO and Partner. He is a member of the expert jury of Venture Kick, a Swiss institution to finance and promote start-ups and acts as lecturer for workshops on valuation and financing. Besides his experience in the valuation field in a variety of industries in Europe and North America, he has developed the global life sciences and Biotech database Biotechgate, which became Venture Valuation’s second business unit. He was also responsible and involved in other large internet projects, such as the development of the partnering software partneringOneTM, which is used every year at life sciences conferences all over the world. Jost has studied at several Swiss Universities and holds a Master in business economics as well as a Master in Advanced Studies in IT.

LinkedIn

Susanne E. Acklin

Susanne E. Acklin

Senior Advisor & VP Life Sciences Ph.D.

Susanne has been an expert advisor with Venture Valuation since foundation and is integrally involved in company and product valuation and assessment. She has 15 years of experience in the global pharmaceutical and biotechnology industry and her professional background includes executive roles at Axentis Pharma (Chief Operating Officer); Viron Therapeutics (Senior VP Product Development), the University of Western Ontario (Associate Director, Business Development and Technology Transfer); and Eli Lilly and Company (Manager Regulatory Affairs and Clinical Research). Susanne holds a Ph.D. in Neurophysiology/Neuropharmacology from the Biocenter of the University of Basel, Switzerland and completed post doctoral studies in medical sciences at the University of Toronto, Canada.

Aitana Peire

Business Analyst Ph.D.

Before joining Venture Valuation in 2013 as business analyst, Aitana worked as Pharma equity research analyst for Kepler Cheuvreux, covering Valneva, Basilea and Lonza. Prior to that, she worked as consultant for Stratas Partners, based in Basel, focusing on projects on market access, pricing and reimbursement, and budget impact modelling. Finally, she started her career in Finance with a position as investment analyst for London-based hedge fund Carval Investors, as part of the NPL team, where she assisted in the pricing and performance analysis of investments across several geographies. Aitana holds a PhD in Evolutionary Genetics from the University of Groningen (Netherlands) and is a CFA Level II candidate.

LinkedIn

Ronald E. Layden

Senior Advisor & VP Life Sciences Ph.D.

Ron joined Venture Valuation in 2001 and is mainly involved in company and product valuations and assessment. His previous roles include CEO of a biotechnology company, venture capitalist and co-founder of several businesses; senior manager in the pharmaceutical industry with assignments at Roche, Bayer and Eli Lilly. He also has research and laboratory experience in oil field chemistry, cell biology, molecular biology and genetics. Ron holds a Ph.D. in Biochemistry from the University of Western Ontario in Canada.

Alan Jones

Senior Business Development Executive

Alan joined Venture Valuation in 2012, he is responsible for conducting business development for the Biotechgate database which is a global, comprehensive information service encompassing the Life Science industry. Alan has extensive experience in the business development of innovative information services within the life sciences and previously worked for many years within the business development team at Pharmalicensing.

LinkedIn

Barbara Cambridge

Business Development Executive

Barbara joined Venture Valuation in early 2014. She has vast experience in multiple roles for a number of life science companies. Barbara is now a part of the Biotechgate business development team and is also responsible for the companies social media activities.

LinkedIn

Wim Troch

Wim Troch

Business Development Executive

Wim is multi-lingual with many years of business development experience within several sectors (and hopefully the best is still to come). He started his career in London after which his professional travels took him to Russia, Spain, Australia and recently to Switzerland. He has over 5 years experience in the Life Science sector.

Konstantinos Dimitrakopoulos

Konstantinos Dimitrakopoulos

Business Analyst Trainee M.A.

Konstantinos joined Venture Valuation after graduating with a masters degree in Quantitative Economics and Finance from the University of St. Gallen. With a bachelors in Statistics and Insurance from the University of Piraeus, he is genuinely interested in the quantitative aspects relating to the valuation of life-sciences companies - both the clinical and the financial ones.

Denis Tétaz

IT Intern BscIS

Denis is currently finishing his Master of information systems (MScIS) from the Universities of Lausanne and Neuchâtel. During his internship at Venture Valuation, Denis is writing his Master thesis and conducting some research.

LinkedIn

Mariko Hirano

Head of Japan Operations M.Sc., M.A.

Mariko has extensive experience in business development in Japan, the U.S., and Europe; and is the co-founder of a biotechnology company in Tokyo, Japan. Her former positions include Head of Japan Operations at ACLARA BioSciences (now Monogram Biosciences) in Mountain View, California; Program Manager at Stanford University’s U.S.-Asia Technology Management Center; and managing position at Rhône-Poulenc Santé (now Sanofi-Aventis) in Japan. Mariko holds a M.S. in Technology Management from Pepperdine University in Los Angeles, California, and a M.A. in French from Sophia University in Tokyo.

Sonia Thomas

Sonia Thomas

Director VV Data Processing, India M.Sc.

Sonia is Director of VV Data Processing based in Kerala, India and is responsible for the day to day information management for the Global Biotechgate Database. She has over 10 years of experience in Operations, with focus on Quality Management, in the ITES industry. In a previous role, she developed and implemented processes and facilitated resource mobilization for start-up ITES companies. Sonia holds an M.Sc. in Biotechnology and has completed additional training including NQA certification as ISO 9001:2000 QMS Auditor.

LinkedIn

Sarath C.P.

Managing Director VV Data Processing, India M.Sc., MCP

Sarath is the Managing Director of VV Data Processing based in Kerala, India which is responsible for data management for the Global Biotechgate Database. He has over ten years of experience in System Analysis, Design and Management and played a key role in IT companies like M2 Comsys and Ascentia Technologies. Sarath obtained his Masters Degree in Biotechnology from Mahatma Gandhi University, India and pursued research in Bioinformatics.

Dieter Hammer

Representative Director, Germany M.A.

Dieter has been a valuation expert and advisor with Venture Valuation since 2001 and has many years of professional experience as a consultant in various industries. Next to his analytical experience he is specialised in moderation and conflict resolution. He is an accredited commercial mediator with the Chamber of Commerce and Industry, Munich, and the World Intellectual Property Organisation (WIPO), Geneva, in the area of intellectual property disputes. Dieter holds a masters degree in philosophy from the Jesuite School of Philosophy, Munich, Germany.

Son U Michael Paik

Representative Director, Asia JD / MBA, (Columbia Law School)

Michael is a Venture Valuation Representative for Asia, based in Seoul Korea. Michael has served as counsel to many US and European start-ups and venture capital funds while at Wilson Sonsini Goodrich & Rosati (Palo Alto) and US investment banks while at Cahill Gordon & Reindel (NY). He is licensed as an attorney in both New York and California. Michael Paik was previously the Senior Vice President of Risk Management at STX Europe, Chief Technology Officer at Seoul National University's R&DB Foundation and Director of Technology Incubation at SNU's College of Engineering. He was General Counsel & Director of the Global Legal Department at STX Corporation, Hankook Tire Company, and the Inje Foundation / Paik Hospitals, where he continues to serve as a Trustee. He has been Counsel to the Korean Venture Capital Association, the Korean Nurses' Association and the Incheon Free Economic Zone Authority, as well as Samsung Electronics, Samsung Venture Investment Corporation, LG Electronics, LG Venture Investments and several other Korean companies. Michael has taught as a Professor at Yonsei University's College of Law, the Judicial Research & Training Institute, and Seoul National University's College of Engineering, and he graduated from Syracuse University (BA, Economics, 1991), Yale University (MBA, 1995) and Columbia University (JD, 1998).

Kyung-Ho (David) Cheoun

Representative Director Korea

David holds master’s and bachelor's degrees in pharmacology and pharmacy, respectively, from Choongang University and he is a licensed pharmacist. Prior to joining Venture Valuation, David was Managing Director of the Biotechnology and Pharmaceuticals Department at the Korean Pharmaceutical Manufacturers Association (where he was responsible for interacting with various regulatory agencies and ministries of the Korean government), Managing Director of Regulatory Affairs at Korea Union Pharmaceuticals (where he was responsible for new licensing and business development with international pharmaceuticals) and a Senior Manager at CJ Pharmaceuticals (where he managed interactions with the Korean Food and Drug Administration, for submissions and approvals). He has a wide variety of business experience, with regard to Korean pharmaceuticals domestic and overseas activities as well as international pharmaceuticals entering into the Korean market. Over the past thirty years, David has developed extensive industry and government contacts helpful to domestic and international clients, and he serves as the principal business development contact for Venture Valuation in Seoul.